By Billy Gray
Roche is scheduled to report results for 2025 on Thursday. Here is what you need to know.
SALES FORECAST: The Swiss drugmaker is expected to post sales of 61.47 billion Swiss francs ($80.75 billion), according to consensus estimates provided by Visible Alpha. Roche posted 60.5 billion francs in 2024 sales.
CORE EARNINGS PER SHARE: The company is expected to post core earnings per share of 19.70 francs, according to Visible Alpha. Roche posted core EPS of 18.80 francs for 2024.
WHAT TO WATCH
Roche shares rose 20% over the past 12 months to close at 359.40 francs on Tuesday.
--OBESITY CANDIDATES: Roche is moving to become a strong player in the bustling weight-loss treatment market before 2030, but analysts are split on the potential of its experimental CT-388 drug. UBS analysts said its recent midstage study results looked "robust." But analysts from Jefferies said they were "not sure how CT-388 will be differentiated in an increasingly crowded market," adding that Roche will need to show a path to commercial relevance in an obesity field that is bound to fragment.
--PIPELINE STRENGTH: Stronger-than-expected results from a trial of the experimental breast cancer pill giredestrant were a positive surprise, J.P.Morgan analysts said in November. That treatment has the potential to capture around $5 billion in sales, they added.
--U.S. PRICING: The White House is intent on getting Americans to pay less for prescription drugs by tethering U.S. prices to those overseas, and investors in the sector are closely monitoring how that might play out. "I think it is important that people understand that countries need to pay and invest their fair share for the innovation that helps their citizens," Teresa Graham, chief executive of Roche's pharmaceutical division, said.
Write to Billy Gray at william.gray@wsj.com
(END) Dow Jones Newswires
January 28, 2026 06:22 ET (11:22 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
Comments